BioCryst Pharmaceuticals Management
Management criteria checks 3/4
BioCryst Pharmaceuticals' CEO is Charlie Gayer, appointed in Aug 2025, has a tenure of less than a year. total yearly compensation is $3.38M, comprised of 16.1% salary and 83.9% bonuses, including company stock and options. directly owns 0.17% of the company’s shares, worth $2.71M. The average tenure of the management team and the board of directors is 3 years and 4.4 years respectively.
Key information
Charlie Gayer
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 16.14% |
| CEO tenure | less than a year |
| CEO ownership | 0.2% |
| Management average tenure | 3yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Earnings Beat: BioCryst Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 06
BioCryst To Buy Astria: A Calculated Gamble That Is Not Without Risk
Oct 15BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 07
ORLADEYO Pipeline Will Deliver New Therapeutic Opportunities
ORLADEYO's revenue growth, patient conversion, and reduced royalty payments enhance profitability, cash flow, and financial stability for BioCryst Pharmaceuticals.BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
Feb 25BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Fly 25% But Investors Aren't Buying For Growth
Feb 15BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
Dec 09BioCryst's Orladeyo Outperforms, But Competition Remains A Threat (Rating Upgrade)
Sep 29Analysts Are Upgrading BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its Latest Results
Aug 08Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
Jul 21BioCryst: Estimate-Beating Q1 But Risks Are Considerable
May 07Insufficient Growth At BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Hampers Share Price
Apr 29BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look
Feb 27BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Jan 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$9m |
| Jun 30 2025 | n/a | n/a | -US$36m |
| Mar 31 2025 | n/a | n/a | -US$53m |
| Dec 31 2024 | US$3m | US$545k | -US$89m |
| Sep 30 2024 | n/a | n/a | -US$124m |
| Jun 30 2024 | n/a | n/a | -US$146m |
| Mar 31 2024 | n/a | n/a | -US$209m |
| Dec 31 2023 | US$2m | US$495k | -US$227m |
| Sep 30 2023 | n/a | n/a | -US$236m |
| Jun 30 2023 | n/a | n/a | -US$243m |
| Mar 31 2023 | n/a | n/a | -US$226m |
| Dec 31 2022 | US$2m | US$449k | -US$247m |
Compensation vs Market: Charlie's total compensation ($USD3.38M) is below average for companies of similar size in the US market ($USD5.37M).
Compensation vs Earnings: Charlie's compensation has increased whilst the company is unprofitable.
CEO
Charlie Gayer (53 yo)
Mr. Charles K. Gayer is President at BioCryst Pharmaceuticals, Inc. since August 1, 2025. He served as the Senior Vice President at BioCryst Pharmaceuticals, Inc. since January 2020 until August 1, 2025 an...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | less than a year | US$3.38m | 0.17% $ 2.7m | |
| Senior VP | 19.3yrs | US$3.24m | 0.069% $ 1.1m | |
| CFO & Head of Corporate Development | less than a year | no data | no data | |
| Manager of Investor Relations | no data | no data | no data | |
| Chief People Officer & Chief Communications Officer | less than a year | no data | no data | |
| Chief Development Officer | 17.5yrs | US$2.66m | no data | |
| Chief Discovery Officer | 12.3yrs | US$2.57m | no data | |
| Chief Data Innovation Officer | 4.2yrs | no data | no data | |
| Chief Strategy Officer | 3.3yrs | no data | no data | |
| Chief Business Development Officer | 3yrs | no data | no data | |
| Chief Medical Officer | 1.3yrs | no data | no data | |
| Chief Commercial Officer | no data | no data | no data |
Experienced Management: BCRX's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | no data | US$3.38m | 0.17% $ 2.7m | |
| Independent Director | 4.5yrs | US$347.97k | 0.037% $ 583.3k | |
| Independent Director | 5.9yrs | US$342.97k | 0.025% $ 383.6k | |
| Director | less than a year | no data | 0.0015% $ 24.0k | |
| Independent Director | 7.1yrs | US$342.97k | 0.025% $ 391.6k | |
| Independent Chair | 14yrs | US$377.97k | 0.041% $ 642.0k | |
| Director | 19yrs | US$8.32m | 0.49% $ 7.7m | |
| Independent Director | 4.3yrs | US$330.47k | 0.028% $ 432.5k | |
| Independent Director | 3.9yrs | US$330.47k | 0.0086% $ 134.5k | |
| Independent Director | 4.3yrs | US$335.47k | 0.014% $ 217.0k |
Experienced Board: BCRX's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 02:51 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioCryst Pharmaceuticals, Inc. is covered by 28 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |